Signe Benzon Larsen1,2, Christian Dehlendorff3, Charlotte Skriver4, Anton Pottegård5, Søren Friis4, Martin Andreas Røder6,7, Klaus Brasso6,7, Anne Katrine Duun-Henriksen3. 1. Urological Research Unit, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. signe.liv.benzon.larsen@regionh.dk. 2. Survivorship and Inequality in Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark. signe.liv.benzon.larsen@regionh.dk. 3. Statistics and Data Analysis, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark. 4. Cancer Surveillance and Pharmacoepidemiology, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark. 5. Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark. 6. Urological Research Unit, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. 7. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Abstract
PURPOSE: To investigate differences in prescription rates of commonly used drugs among prostate cancer patients and cancer-free comparisons and between patients diagnosed with localized and non-localized disease. METHODS: We conducted a register-based study including all men aged 50-85 years diagnosed with prostate cancer in Denmark from 1998 to 2015 and an age-matched cancer-free comparison cohort. We calculated the number of new and total prescriptions from three years before to three years after the date of diagnosis of the case for selected drug classes divided by the number of person-months and stratified by stage at diagnosis. RESULTS: We included 54,286 prostate cancer patients and 249,645 matched comparisons. 30,712 patients were diagnosed with localized disease and 12,884 with non-localized disease. The rates of new prescriptions increased considerably among patients within the year before the diagnosis. Hereafter the rates varied between drug classes. For most drug classes, total prescription rates for patients and comparisons increased similarly in the study period. Total prescription rates varied between men with localized and non-localized disease for all drug classes apart from statins. CONCLUSION: Our findings indicate that a large proportion of prostate cancer cases are likely diagnosed during medical work-up for other reasons than prostate cancer. Increased rates occur within the last year before diagnosis and future studies on the interaction between drug use and prostate cancer should at least include a one year pre-diagnostic lag-time. Post-diagnostic prescription rates demonstrated an increased use of drugs most likely associated with the consequences of the disease.
PURPOSE: To investigate differences in prescription rates of commonly used drugs among prostate cancer patients and cancer-free comparisons and between patients diagnosed with localized and non-localized disease. METHODS: We conducted a register-based study including all men aged 50-85 years diagnosed with prostate cancer in Denmark from 1998 to 2015 and an age-matched cancer-free comparison cohort. We calculated the number of new and total prescriptions from three years before to three years after the date of diagnosis of the case for selected drug classes divided by the number of person-months and stratified by stage at diagnosis. RESULTS: We included 54,286 prostate cancer patients and 249,645 matched comparisons. 30,712 patients were diagnosed with localized disease and 12,884 with non-localized disease. The rates of new prescriptions increased considerably among patients within the year before the diagnosis. Hereafter the rates varied between drug classes. For most drug classes, total prescription rates for patients and comparisons increased similarly in the study period. Total prescription rates varied between men with localized and non-localized disease for all drug classes apart from statins. CONCLUSION: Our findings indicate that a large proportion of prostate cancer cases are likely diagnosed during medical work-up for other reasons than prostate cancer. Increased rates occur within the last year before diagnosis and future studies on the interaction between drug use and prostate cancer should at least include a one year pre-diagnostic lag-time. Post-diagnostic prescription rates demonstrated an increased use of drugs most likely associated with the consequences of the disease.
Authors: Timothy J Daskivich; Kang-Hsien Fan; Tatsuki Koyama; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Janet L Stanford; Antoinette M Stroup; Mark S Litwin; David F Penson Journal: Ann Intern Med Date: 2013-05-21 Impact factor: 25.391
Authors: Konstantina G Yiannopoulou; Aikaterini I Anastasiou; Konstantinos Kontoangelos; Charalambos Papageorgiou; Ioannis P Anastasiou Journal: Curr Urol Date: 2020-12-18
Authors: Anne Sofie Friberg; Klaus Brasso; Signe Benzon Larsen; Elisabeth Wreford Andersen; Anja Krøyer; John Thomas Helgstrand; Martin Andreas Røder; Nina Klemann; Lars Vedel Kessing; Christoffer Johansen; Susanne Oksbjerg Dalton Journal: Psychooncology Date: 2021-07-20 Impact factor: 3.894